Endocrine Abstracts

In acromegaly, treatment with somatostatin analogs (SSA) normalizes growth hormone (GH) and insulin-like growth factor 1 (IGF1) secretion in about half of the patients. Usually, the disease relapses biochemically within few months after treatment withdrawal.We present two acromegalic patients, women of 49 and 53 years at diagnosis, respectively, who achieved stable remission of the disease after medical treatment withdrawal. One had a microadenoma, the o...

Acromegaly control/remission is defined by stringent criteria: normal age-/sex-adjusted IGF1 and random GH (GHr) <1 ng/ml or a GH nadir (GHn) during oral glucose tolerance test (OGTT) of <0.4 ng/ml. However discordances between GH and IGF1 have been recorded in about 30% of patients. We retrospectively analyzed the evolution in patients with acromegaly and discordant GH–IGF1 levels while being treated with somatostatin analogs (SSA) and/or cabergoline (CAB).<p...